Stock ARCT ARCTURUS THERAPEUTICS HOLDINGS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Arcturus Therapeutics Holdings Inc.

Equities

ARCT

US03969T1097

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 20:47:06 02/05/2024 BST 		5-day change 1st Jan Change
26.23 USD -6.02% Intraday chart for Arcturus Therapeutics Holdings Inc. -0.08% -17.06%
03-27 Arcturus Therapeutics Holdings Insider Sold Shares Worth $610,574, According to a Recent SEC Filing MT
03-21 Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing MT

Business Summary

Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.

Number of employees: 180

Sales per Business

USD in Million2022Weight2023Weight Delta
Nucleic Acid-focused Technology
100.0 %
206 100.0 % 167 100.0 % -19.03%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
206 100.0 % 167 100.0 % -19.03%

Managers

Managers TitleAgeSince
Joseph Payne CEO
 Chief Executive Officer 52 28/02/13
Andrew Sassine DFI
 Director of Finance/CFO 59 31/08/19
Padmanabh Chivukula COO
 Chief Operating Officer 45 31/12/12
Juergen Froehlich CTO
 Chief Tech/Sci/R&D Officer 68 28/02/23
Neda Safarzadeh IRC
 Investor Relations Contact - -
Lance Kurata LAW
 General Counsel 54 09/08/20
Kevin T. Skol PRN
 Corporate Officer/Principal - 31/12/01

Members of the board

Members of the board TitleAgeSince
Edward W. Holmes BRD
 Director/Board Member 83 31/08/19
James F. Barlow BRD
 Director/Board Member 65 26/05/18
Peter Farrell CHM
 Chairman 81 26/05/18
Andrew Sassine DFI
 Director of Finance/CFO 59 31/08/19
Magda Marquet BRD
 Director/Board Member 65 26/05/18
Jing Marantz BRD
 Director/Board Member 59 06/12/21
Joseph Payne CEO
 Chief Executive Officer 52 28/02/13
John Markels BRD
 Director/Board Member 58 07/12/22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 26,928,041 24,573,463 ( 91.26 %) 0 91.26 %

Shareholders

NameEquities%Valuation
Federated Global Investment Management Corp.
17.50 %
4,711,512 17.50 % 159 M $
BlackRock Advisors LLC
8.242 %
2,218,403 8.242 % 75 M $
ARK Investment Management LLC
6.278 %
1,689,649 6.278 % 57 M $
STATE STREET CORPORATION
6.055 %
1,629,666 6.055 % 55 M $
Joseph Payne
5.499 %
1,480,097 5.499 % 50 M $
Vanguard Fiduciary Trust Co.
5.418 %
1,458,380 5.418 % 49 M $
Nikko Asset Management Americas, Inc.
4.907 %
1,320,652 4.907 % 45 M $
Nikko Asset Management Americas, Inc.
4.907 %
1,320,652 4.907 % 45 M $
SUMITOMO MITSUI TRUST HOLDINGS, INC.
4.743 %
1,276,519 4.743 % 43 M $
Dimensional Fund Advisors LP
4.046 %
1,088,930 4.046 % 37 M $

Company contact information

Arcturus Therapeutics Holdings, Inc.

10628 Science Center Drive Suite 250

92121, San Diego

+

http://www.arcturusrx.com
address Arcturus Therapeutics Holdings Inc.(ARCT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Arcturus Therapeutics Holdings Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
27.91 USD
Average target price
67.89 USD
Spread / Average Target
+143.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ARCTURUS THERAPEUTICS HOLDINGS INC. Stock Arcturus Therapeutics Holdings Inc.
-17.06% 752M
MODERNA, INC. Stock Moderna, Inc.
+26.34% 42.68B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.87% 42.4B
LONZA GROUP AG Stock Lonza Group AG
+45.32% 40.04B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.63% 24.94B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.44% 18.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.60% 12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.96% 11.95B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-1.78% 11.55B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ARCT Stock
  4. Company Arcturus Therapeutics Holdings Inc.